Zhang, M., Porter, B., Pfaff, K., Carlisle, A., Chen, G., Debaize, L., Abdulkarim, S., Wang, H., Mai, J., Batingana, A., Weekes, J., Branch, P., Guerrero, L., McDonough, M., Merryman, R., Ryan, C., Kim, A., Rodig, S., Murakami, M. (2025). Baseline intratumoral CD4⁺ T-cell abundance and frequency correlates with durable clinical response to acalabrutinib, venetoclax, and obinutuzumab (AVO) treatment in Mantle Cell Lymphoma. Blood. https://doi.org/10.1182/blood-2025-3551